Iterum Therapeutics Provides Update on FDA Advisory Committee Discussion of Oral Sulopenem for the Treatment of uUTI in Adult Women
FDA Decision Expected by PDUFA Goal Date of October 25, 2024Potential to be First Oral Penem Approved in the U.S.DUBLIN and CHICAGO, Sept. 10, ...
Researchers identify new tools for anti-Acinetobacter drug development and AMR preparedness
University of Liverpool researchers have engineered a library of strains that can be used to develop new antibacterial ...
The Economist1d
Ara Darzi on why antibiotic resistance could be deadlier than cancer
Radical action is needed. For only the second time in its history, the UN General Assembly will meet this week to address ...
Nursing Times1d
Understanding microbiology tests and interpreting the results
This area of work is becoming increasingly important as cases of multi-drug resistant (MDR ... Microbial colonisation of the urinary tract of older people and those with indwelling urinary catheters ...
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
Bucillamine (N- (mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years.
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are candidates for systemic therapy, ...
India Education Diary7d
Researchers Uncover Innovative Tools for Combatting Acinetobacter and Enhancing AMR Readiness
University of Liverpool researchers have engineered a library of strains that can be used to develop new antibacterial ...
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...